A study titled "ANTI-CATARACT EFFECTS OF CINERARIA MARITIMA EYE DROPS IN THE PROGRESSION OF IMMATURE CATARACT: A PILOT OPEN-LABEL PROSPECTIVE OBSERVATIONAL STUDY" is a Pilot Open-Label Prospective Observational Study of  2 years and 6 months duration with a Primary Objective to evaluate the effects of Cineraria maritima eye drops on the signs & symptoms of cataract, in the improvement of visual acuity using Snellen’s chart and Jaeger’s chart reading and to evaluate the change in grading of cataract using Slit lamp Biomicroscopic examination. Secondary Objective is to evaluate the anti-cataract effects of Cineraria maritima eye drops on visual scores & quality of life based on VFQ-25. Patients between 40 to 80 years of age, both gender, visual acuity better than or equal to 6/60 Snellen chart, and patients who meet the diagnostic standards of immature cataract using slit lamp Biomicroscopic examination will be included in study. Patients suffering from congenital Cataract, mature and hypermature Cataract, Glaucoma, Diabetic Retinopathy, Hypertensive retinopathy, Macular degeneration, Retinitis pigmentosa, Patients with uncontrolled blood sugar and blood pressure, Patients who are under steroid treatment or Immunosuppressive therapy or any Cataract inducing medications, patients unwilling to participate in the study will be excluded from the study.  Primary outcome will be change in symptoms & signs– blurring of vision, visualization of non-existing things, nyctalopia, hemeralopia, glare, intra-ocular pressure, unaided distant visual acuity, pin hole vision, best corrected distant visual acuity using grading pattern on quarterly basis by Snellen’s chart and Jaeger’s chart reading  at baseline and at every quarterly follow up & change in Grading of cataractous lens,, according to lenticular opacity classification system III to assess changes in the area and density of lenticular opacity by Slit lamp Biomicroscopic examination, in tangentional sectioning and retro illumination technique at baseline, 6^th month, 12^th month and at the end of treatment (18th month) & Secondary outcome will be Change in visual score & quality of life to be assessed by VFQ-25 at baseline and at every quarterly follow up and at the end of treatment (18^th month).